Fundz

ETON PHARMACEUTICALS

Biotechnology, Healthcare, Health Care

Eton Pharmaceuticals is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.

Key facts

Employees
39
Industries
Biotechnology, Healthcare, Health Care
Status
Public (ETON)
Website
etonpharma.com
LinkedIn
Company page

Recent activity at ETON PHARMACEUTICALS

  • : Eton Pharmaceuticals Acquires Exclusive U.S. Rights to LIBERVANT® from Aquestive Therapeutics
  • : SEC 8-K (1.01): On October 13, 2026, Eton Pharmaceuticals, Inc. entered into a license agreement with Aquestive Therapeutics, Inc. The agreement grants Eton exclusive U.S. rights to commercialize LIBERVANT® (diazepam) buccal film for the acute treatment of seizure clusters in patients with epilepsy. Eton paid an upfront license fee of $10.0 million and is responsible for up to $47.5 million in milestone payments tied to regulatory approvals and sales achievements. Additionally, a supply agreement ensures Aquestive will be the exclusive manufacturer of the product for an initial term of 20 years, with automatic renewals unless notice is given. This strategic acquisition positions Eton to expand its epilepsy treatment offerings pending applicable regulatory approvals.
  • : SEC 8-K (8.01): On September 28, 2026, Eton Pharmaceuticals, Inc. launched IMPAVIDO® (miltefosine) capsules. This product launch includes the integration of Eton Cares patient support, which offers a $0 co-pay for eligible commercially insured patients and expanded patient assistance programs. This initiative potentially enhances patient access to necessary medication and reflects Eton's commitment to patient support. The press release related to this launch is attached as Exhibit 99.1.
  • : SEC 8-K (1.01): On July 31, 2026, Eton Pharmaceuticals, Inc. entered into a material license agreement with Auson Pharmaceuticals Inc. for the product candidate ASN-001 (timolol topical gel), intended for treating proliferating superficial infantile hemangiomas. Eton will pay an upfront fee of $3 million and is responsible for milestone payments totaling $28.5 million if certain sales thresholds are met post-FDA approval. The company also commits to running a bioavailability bridging study, aiming to submit a New Drug Application in the second half of 2027, which could significantly impact Eton's product pipeline and revenue potential. The press release detailing the transaction was issued on August 5, 2026.
  • : SEC 8-K (5.02): On July 31, 2026, Eton Pharmaceuticals, Inc. appointed Danka Radosavljevic as Chief Operating Officer. Ms. Radosavljevic has been with the company since 2017, previously serving as Executive Vice President, Operations, where she oversaw various key areas including quality and product development. Her compensation package includes a base salary of $520,800 along with an annual discretionary bonus target of 50% of her base salary, contingent upon meeting performance targets set by the Board. This appointment signifies a strategic move to enhance operational leadership within the company.
  • : SEC 8-K (8.01): On July 29, 2026, Eton Pharmaceuticals, Inc. announced through a press release the submission of a prior approval supplement aimed at expanding the indication of their product KHINDIVI® (hydrocortisone) oral solution. This strategic move indicates the company's intention to enhance its market presence and potentially increase sales through a broader application of the medication. The press release is documented as Exhibit 99.1 attached to the filing, highlighting the company's ongoing efforts in product development and regulatory approvals.
  • : SEC 8-K (1.01): On May 18, 2026, Eton Pharmaceuticals, Inc. entered into a supply and distribution agreement with Knight Therapeutics, Inc., granting Eton the United States commercialization rights to IMPAVIDO® (miltefosine) oral capsules. The deal involves a total fixed payment of $4.25 million over several years, with an initial term ending on March 31, 2032. Additionally, Eton will share revenue from net sales, providing 55% on sales up to $7 million per year and 50% thereafter. The commercialization rights will commence on September 26, 2026, with an estimated 2025 U.S. sales of $8.1 million for IMPAVIDO® as per Symphony Health data.
  • : SEC 8-K (8.01): On May 1, 2026, Eton Pharmaceuticals, Inc. announced the launch of HEMANGEOL® (propranolol) Oral Solution, the only FDA-approved treatment for infantile hemangioma, a time-sensitive pediatric rare disease. The company has implemented the Eton Cares patient support program, which includes a $0 co-pay for eligible patients with commercial insurance, along with expanded patient assistance programs. This launch signifies a critical step in addressing a significant medical need in pediatric care. The press release detailing this announcement was attached as Exhibit 99.1 to the filing.
  • : SEC 8-K (8.01): On April 27, 2026, Eton Pharmaceuticals, Inc. announced a pilot study for its product candidate ET-700, an extended-release formulation of zinc acetate aimed at treating Wilson disease. This study will compare ET-700 with Galzin® and a placebo, highlighting the company's commitment to advancing treatment options for this condition. The press release serves to inform stakeholders about the progress of clinical development and the strategic focus on addressing unmet medical needs. The full details are available in the attached press release as Exhibit 99.1.
  • : SEC 8-K (8.01): On April 27, 2026, Eton Pharmaceuticals, Inc. announced the initiation of a pilot study for its product candidate ET-700, an extended-release formulation of zinc acetate. This study aims to compare ET-700 with Galzin® and a placebo in the treatment of Wilson disease. This event reflects a significant step in the company's drug development efforts, potentially impacting its market position and future revenues. The press release detailing this announcement is included as Exhibit 99.1.

ETON PHARMACEUTICALS funding history

DateRoundAmount
Apr 2020Venture$7.5M
Jun 2017Venture$20.1M

Leadership

  • Sean Brynjelsen, CEO
  • Sean Brynjelsen, Executive Officer, Director
  • Paul Maier, Director
  • Norbert Riedel, Director
  • Charles Casamento, Director
  • Mark Baum, Director
  • Charles Casamento, Director
  • Andrew Boll, Director
  • Mark Baum, Director
  • Sean Brynjelsen, Executive Officer, Director
  • James Gruber, Chief Financial Officer
  • Judith Matthews, Treasurer

Verified email and direct lines for ETON PHARMACEUTICALS’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

ETON PHARMACEUTICALS files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

ETON PHARMACEUTICALS in the news

Companies similar to ETON PHARMACEUTICALS

About ETON PHARMACEUTICALS: questions and answers

What does ETON PHARMACEUTICALS do?

Eton Pharmaceuticals is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.

How many employees does ETON PHARMACEUTICALS have?

ETON PHARMACEUTICALS has about 39 employees.

Has ETON PHARMACEUTICALS raised funding?

Yes. Fundz has recorded 2 funding events for ETON PHARMACEUTICALS. The most recent, $7.5M, was in Apr 2020.

Who leads ETON PHARMACEUTICALS?

Sean Brynjelsen is a CEO at ETON PHARMACEUTICALS.

What is the latest news on ETON PHARMACEUTICALS?

On Oct 15, 2026, Eton Pharmaceuticals Acquires Exclusive U.S. Rights to LIBERVANT® from Aquestive Therapeutics

Is ETON PHARMACEUTICALS a public company?

Yes. ETON PHARMACEUTICALS is publicly traded under the ticker ETON.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches ETON PHARMACEUTICALS across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.